Effect of Curumin (tumeric) on type 2 diabetes

Evaluation of anti-oxidant and anti-inflammatory effects of Curcumin in type 2 diabetes patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201505301165N4

Enrollment

120

Registered

2015-06-07

Start date

2015-06-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention: Curcumin capsule, twice a day, until 3 months. Intervention 2: Control:Placebo capsule, 500 mg twice a day, until 3 months.

Treatment - Drugs

Placebo

Intervention: Curcumin capsule, twice a day, until 3 months

Control:Placebo capsule, 500 mg twice a day, until 3 months

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of type 2 diabetes (FBS =126 mg/dl, HbA1C =6.5%); type 2 diabetes patients under standard anti-diabetics agents; adult patients (18 to 65 year old). Exclusion criteria: pregnancy or breast feeding; lack of compliance with the study medication; impossibility to give informed consent; participation on an other concomitant clinical trial; presence of malignancies; chronic liver disease (ALT = 3 folds of upper limit of normal value range; renal failure (serum creatinine =2.0 mg/dL or on dialysis); subjects receiving hormonal agents; subjects receiving other herbal medicines; subjects with secondary causes of hyperglycemia (receiving steroids or with pancreatic cancer) subjects with acute infections or chronic inflammatory diseases (rheumatoid arthritis); hypersensitivity to the study medication; endocrine disease (hypothyroidism or hyperthyroidism); obsessive compulsive disorder.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting insulin. Timepoint: at baseline and 3 months after intervention. Method of measurement: pmol/L.;Fasting Blood Sugar. Timepoint: at baseline and 3 months after intervention. Method of measurement: mg/dl.;C peptide. Timepoint: at baseline and 3 months after intervention. Method of measurement: ng/ml.;HbA1C. Timepoint: at baseline and 3 months after intervention. Method of measurement: perecent.;MDA. Timepoint: at baseline and 3 months after intervention. Method of measurement: nmol/ml.;TNF-a. Timepoint: at baseline and 3 months after intervention. Method of measurement: pg/ml.;Superoxidase dismutase (SOD). Timepoint: at baseline and 3 months after intervention. Method of measurement: U/ml.;Plasma Total Antioxidant Capacity (TAO). Timepoint: at baseline and 3 months after intervention. Method of measurement: nmol/mg.;Leptin. Timepoint: at baseline and 3 months after intervention. Method of measurement: ng/ml.;Adiponectin. Timepoint: at baseline and 3 months after intervention. Method of measurement: ng/ml.;Ghreline. Timepoint: at baseline and 3 months after intervention. Method of measurement: pmol/L.;Glucagon like peptide-1. Timepoint: at baseline and 3 months after intervention. Method of measurement: pmol/L.;C Reactive Protein (CRP). Timepoint: at baseline and 3 months after intervention. Method of measurement: mg/dl.	—

Measure

Time frame

Fasting insulin. Timepoint: at baseline and 3 months after intervention. Method of measurement: pmol/L.;Fasting Blood Sugar. Timepoint: at baseline and 3 months after intervention. Method of measurement: mg/dl.;C peptide. Timepoint: at baseline and 3 months after intervention. Method of measurement: ng/ml.;HbA1C. Timepoint: at baseline and 3 months after intervention. Method of measurement: perecent.;MDA. Timepoint: at baseline and 3 months after intervention. Method of measurement: nmol/ml.;TNF-a. Timepoint: at baseline and 3 months after intervention. Method of measurement: pg/ml.;Superoxidase dismutase (SOD). Timepoint: at baseline and 3 months after intervention. Method of measurement: U/ml.;Plasma Total Antioxidant Capacity (TAO). Timepoint: at baseline and 3 months after intervention. Method of measurement: nmol/mg.;Leptin. Timepoint: at baseline and 3 months after intervention. Method of measurement: ng/ml.;Adiponectin. Timepoint: at baseline and 3 months after intervention. Method of measurement: ng/ml.;Ghreline. Timepoint: at baseline and 3 months after intervention. Method of measurement: pmol/L.;Glucagon like peptide-1. Timepoint: at baseline and 3 months after intervention. Method of measurement: pmol/L.;C Reactive Protein (CRP). Timepoint: at baseline and 3 months after intervention. Method of measurement: mg/dl.

—

Secondary

Measure	Time frame
Body Mass Index (BMI). Timepoint: at the baseline and 3 month after treatment. Method of measurement: kg/m2.;Alanine transaminase (ALT). Timepoint: at the baseline and 3 month after treatment. Method of measurement: U/L.;Aspartate transaminase (AST). Timepoint: at the baseline and 3 month after treatment. Method of measurement: U/L.;Serum Creatinine. Timepoint: at the baseline and 3 month after treatment. Method of measurement: mg/dl.	—

Measure

Time frame

Body Mass Index (BMI). Timepoint: at the baseline and 3 month after treatment. Method of measurement: kg/m2.;Alanine transaminase (ALT). Timepoint: at the baseline and 3 month after treatment. Method of measurement: U/L.;Aspartate transaminase (AST). Timepoint: at the baseline and 3 month after treatment. Method of measurement: U/L.;Serum Creatinine. Timepoint: at the baseline and 3 month after treatment. Method of measurement: mg/dl.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEbrahim Sahebi

Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences

ebrahimsahebi@yahoo.com+98 21 8248 2516

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026